Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of$ 0.52. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.62%. A quarter ago, it was expected that this company would post a loss of$ 0.57 per share when it actually produced a loss of $0.46, delivering a surprise of 19.30%.Over the last four quarters, the company has ...